Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Preclinical Development: Overview01:28

Preclinical Development: Overview

5.7K
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
5.7K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Recombinant Protein Drugs: A 2025 Update.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2026
Same author

Biomimetic Protein Materials for Adjuvant-Free Dermal Penetration.

ACS materials letters·2026
Same author

A Structurally Dynamic Pathogen-Mimicking Biomaterial Is an Efficient Activator of Dendritic Cells.

ACS materials letters·2026
Same author

GFP-like protein scaffolds for antigen grafting: Soluble and stable neoantigen display in mammalian-compatible platforms.

Biomaterials advances·2026
Same author

KDEL-mediated modulation of intracellular trafficking in cell-targeted protein drugs.

European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V·2026
Same author

Conjugation strategy shapes antitumor efficacy and enables dose-sparing in non-antibody protein nanoconjugates.

Materials today. Bio·2026

Related Experiment Video

Updated: Dec 28, 2025

Author Spotlight: Standardizing Mouse In Vivo PET Imaging with Body Conforming Molds and Automated Analysis
07:45

Author Spotlight: Standardizing Mouse In Vivo PET Imaging with Body Conforming Molds and Automated Analysis

Published on: October 25, 2024

698

Artificial Inclusion Bodies for Clinical Development.

Julieta M Sánchez1,2, Hèctor López-Laguna1,3,4, Patricia Álamo4,5

  • 1Institut de Biotecnologia i de Biomedicina Universitat Autònoma de Barcelona Bellaterra 08193 Barcelona Spain.

Advanced Science (Weinheim, Baden-Wurttemberg, Germany)
|February 12, 2020
PubMed
Summary

Researchers developed artificial inclusion bodies (ArtIBs) as a novel biomaterial for drug delivery. These chemically defined microparticles mimic bacterial IBs, overcoming limitations for potential biomedical applications.

Keywords:
biomimetic materialscancerdrug releasemicroparticlesrecombinant proteins

More Related Videos

Encapsulated Cell Technology for the Delivery of Biologics to the Mouse Eye
06:10

Encapsulated Cell Technology for the Delivery of Biologics to the Mouse Eye

Published on: March 30, 2020

8.3K
Predicting In Vivo Payloads Delivery using a Blood-brain Tumor-barrier in a Dish
13:34

Predicting In Vivo Payloads Delivery using a Blood-brain Tumor-barrier in a Dish

Published on: April 16, 2019

9.6K

Related Experiment Videos

Last Updated: Dec 28, 2025

Author Spotlight: Standardizing Mouse In Vivo PET Imaging with Body Conforming Molds and Automated Analysis
07:45

Author Spotlight: Standardizing Mouse In Vivo PET Imaging with Body Conforming Molds and Automated Analysis

Published on: October 25, 2024

698
Encapsulated Cell Technology for the Delivery of Biologics to the Mouse Eye
06:10

Encapsulated Cell Technology for the Delivery of Biologics to the Mouse Eye

Published on: March 30, 2020

8.3K
Predicting In Vivo Payloads Delivery using a Blood-brain Tumor-barrier in a Dish
13:34

Predicting In Vivo Payloads Delivery using a Blood-brain Tumor-barrier in a Dish

Published on: April 16, 2019

9.6K

Area of Science:

  • Biomaterials Science
  • Nanotechnology
  • Drug Delivery Systems

Background:

  • Bacterial inclusion bodies (IBs) are microscale protein particles with amyloid structures, known for slow protein release and potential in drug delivery.
  • However, their bacterial origin and variable composition hinder clinical translation.
  • Existing IBs face regulatory hurdles and batch-to-batch inconsistencies.

Purpose of the Study:

  • To develop a cell-free method for fabricating artificial inclusion bodies (ArtIBs).
  • To create chemically defined biomimetic microparticles that replicate the functionalities of natural IBs.
  • To propose ArtIBs as a novel class of biomaterials for biomedical applications, bypassing regulatory issues associated with bacterial IBs.

Main Methods:

  • De novo fabrication of artificial inclusion bodies (ArtIBs) using simple, cell-free physicochemical methods.
  • Utilizing pure protein components in defined quantities for reproducible synthesis.
  • Characterization of ArtIBs for their structural and functional properties.

Main Results:

  • Successfully fabricated ArtIBs, which are chemically defined protein microparticles.
  • ArtIBs demonstrated functionalities similar to natural IBs, including mammalian cell penetration.
  • These artificial structures enable controlled release of functional proteins.

Conclusions:

  • Artificial inclusion bodies (ArtIBs) offer a promising alternative to bacterial IBs for drug delivery.
  • Their defined composition and cell-free fabrication simplify development and regulatory pathways.
  • ArtIBs represent a novel biomaterial category with significant biotechnological and biomedical potential.